title: Angio-oedema as an unusual tolerable side effect of voriconazole therapy.
abstract: Voriconazole (VRC) has not previously been reported to cause angio-oedema. Here, we report a case of angio-oedema associated with VRC therapy. A 37-year-old woman with relapsing invasive vertebral aspergillosis received intravenous VRC and developed angio-oedema 10 days after starting therapy. This condition rapidly diminished after administration of intravenous antihistaminics and did not necessitate cessation of VRC treatment. The treatment was continued for 6 months without recurrence of the symptoms. After 18 months, the patient was in good health. To our knowledge, this is the first report of an angio-oedema associated with VRC.
authors.affiliation: Dr.Lütfi Kırdar Kartal Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey.
authors.forename: Serap
authors.initials: S
authors.lastname: Gençer
authors.affiliation: Dr.Lütfi Kırdar Kartal Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey.
authors.forename: Serdar
authors.initials: S
authors.lastname: Özer
authors.affiliation: Dr.Lütfi Kırdar Kartal Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey.
authors.forename: Güler
authors.initials: G
authors.lastname: Demirhan
authors.affiliation: Dr.Lütfi Kırdar Kartal Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey.
authors.forename: Öznur
authors.initials: Ö
authors.lastname: Ak
authors.affiliation: Dr.Lütfi Kırdar Kartal Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey.
authors.forename: Ayşe
authors.initials: A
authors.lastname: Batırel
mesh_terms: D000328:Adult; D000799:Angioedema / Q000139:chemically induced* / Q000188:drug therapy; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects; D001228:Aspergillosis / Q000188:drug therapy*; D005260:Female; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage / Q000009:adverse effects*; D065819:Voriconazole
chemical_list: D000935:Antifungal Agents; D006634:Histamine H1 Antagonists; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole